

Yanet Estrella Tovar-Calderon, Bachelor¹; Francisco Javier Leal-Vega, MSc¹; Miriam Bobadilla-Del-Valle, PhD¹; JOSE SIFUENTES-OSORNIO, MD, FIDSA⁴ and Alfredo Ponce de Leon, MD¹; ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Oaxaca, Mexico; ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Distrito Federal, Mexico; ³Hospital Universitario UANL, Guadalajara, Jalisco, Mexico; ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Tlalpan, Distrito Federal, Mexico

Session: 63. HAI: VRE Epidemiology
Thursday, October 3, 2019: 12:15 PM

Background. The primary pathogens in genera enterococcus are *E. faecalis* and *E. faecium*, increasing acquired resistance to glycopeptides and β lactamic has done the management more challenging. We aimed to describe the risk factors for acquisition of bacteremia for vancomycin-resistant *E. faecium* (VRE) and ampicillin-resistant *E. faecalis* (ARE) and the 30-day mortality in comparison to susceptible enterococcal bloodstream infection (BSI)

Methods. From 2007- 2017 medical records of all BSI for *E. faecalis* and *E. faecium* were evaluated. Risk factor for acquisition of VRE and ARE as well as the significant variables associated with 30-day mortality for enterococcal BSI were determined by univariate and multivariate analysis. The molecular mechanism of VRE was performed by PCR

Results. There were 192 patients with *E. faecium* BSI of which 107(56%) patients had VRE BSI with 94% VRE strains expressing *vanA* gene. The index bacteremic episodes were classified as nosocomial or healthcare associated in 99%, 102(95%) had hospitalization 1 year before and 101(94%) history of use of antibiotics 3 months earlier, the multivariate analysis showed duration of the previous hospitalization >10 days (OR, 80.18; 95% CI, 1.81–634), use of central venous catheter [OR, 11.15; 95% CI, 2.48–50.2), and endotracheal cannula [OR, 17.91; 95% CI, 1.22–262) as significant associated variables. The mortality for VRE was greater than susceptible *E. faecium* (60% vs. 24%, $P < 0.001$). The only factors for 30-day mortality for *E. faecium* BSI in the multivariate analysis was APACHE II score [OR, 1.45; 95% CI, 1.26–1.66) and patients with chemotherapy of cancer. (OR, 3.52; 95% CI, 1.09–11.39). 147 patients had *E. faecalis* BSI of which 18 (11%) patients had ARE, we did not find relevant clinical differences of ARE in comparison with ampicillin-susceptible *E. faecalis*, neither in risk factors for acquisition of ARE nor 30-day mortality [7(39%) vs. 38(29%), $P = 0.58$] in uni and multivariate analysis

Conclusion. Our evaluation showed in a period of 10 years that VRE expressing *vanA* gene had a strong association with patients with previous nosocomial exposure. Severely ill patients and cancer patients on chemotherapy during the bacteremic episode were the variables more associated with 30-day mortality. ARE is yet of low prevalence and less known, constant surveillance about it is warranted

Disclosures. All authors: No reported disclosures.

574. Reporting of Vancomycin-Resistant *Enterococcus* Bacteremia among National Healthcare Safety Network Acute Care Hospitals

Sukarma S.S. Tanwar, MBBS, MMed, MScPH; Lindsey Lastinger, MPH; Jeneita Bell, MD, MPH; Suparna Bagchi, MSPH, DrPH; Katherine Allen-Bridson, RN, BSN, MScPH, CIC; Margaret Dudeck, MPH, CPH and Jonathan R. Edwards, MStat; Centers for Disease Control and Prevention, Atlanta, Georgia

Session: 63. HAI: VRE Epidemiology
Thursday, October 3, 2019: 12:15 PM

Background. The National Healthcare Safety Network's (NHSN's) Multidrug-resistant Organism/Clostridioides difficile (MDRO/CDI) Module serves as a surveillance platform for tracking antibiotic-resistant laboratory-identified (LabID) organisms. LabID event surveillance, which does not require submission of clinical data to NHSN, provides proxy measures for MDRO burden. While surveillance of some organisms is federally mandated, these requirements do not extend to vancomycin-resistant *Enterococcus* (VRE). We sought to describe the extent of acute care hospital (ACH) participation in NHSN VRE surveillance and identify facility-level factors associated with VRE bacteremia. These could explain differences in VRE incidence and be used in preparation for a national risk-adjusted benchmark.

Methods. ACHs that reported at least one month of facility-wide inpatient (FacWideIN) VRE bacteremia LabID Event data to NHSN in 2017 were included in the analysis. LabID events were categorized as healthcare facility-onset (HO), defined as a laboratory result for a specimen collected ≥ 4 days after admission, or community-onset (CO), defined as a specimen collected < 4 days after admission. Monthly patient day and admission denominators were used to calculate FacWideIN HO incidence and CO prevalence rates. Univariate analyses were performed on facility-level factors from NHSN's annual hospital survey to assess their relationship with HO VRE bacteremia.

Results. A total of 544 HO VRE bacteremia events were reported by 498 hospitals in 37 states. About 67% of reporting hospitals were located in California. The national rate of HO VRE bacteremia was 0.27 per 10,000 patient-days and the CO VRE bacteremia rate was 0.58 per 10,000 admissions. Major medical school affiliation, hospital type, larger number of beds and ICU beds, longer average length of stay and the presence of an oncology unit were significantly associated with HO VRE bacteremia (Table 1).

Conclusion. Based on the VRE data reported to NHSN, certain facility-level factors may contribute to a higher incidence of HO VRE bacteremia. Future analyses can allow us to determine whether these factors are independently associated with VRE. Risk-adjusted surveillance data can help guide facilities and states to compare their burden of VRE to a national benchmark.

Table 1: Facility factors associated with healthcare facility-onset VRE bacteremia

Facility factors	Healthcare facility onset VRE Bacteremia Incidence Rate, per 10,000 patient days	95% Confidence Interval	P-value
Hospital type			
General acute care	0.276	0.253, 0.300	0.0088
Pediatrics or other specialty	0.076	0.035, 0.145	Referent
Total bed size			
< 75 beds	0.106	0.052, 0.195	0.0045
75–157 beds	0.131	0.093, 0.180	0.0002
158–283 beds	0.205	0.169, 0.246	0.0245
≥ 284 beds	0.337	0.305, 0.372	Referent
ICU bed size			
< 8 beds	0.074	0.030, 0.154	0.0015
8–17 beds	0.157	0.115, 0.207	0.0007
18–40 beds	0.179	0.145, 0.218	0.0044
≥ 41 beds	0.347	0.314, 0.382	Referent
Average length of stay			
< 3.4 days	0.107	0.073, 0.151	< 0.0001
3.4–4.0 days	0.139	0.107, 0.177	< 0.0001
4.1–5.0 days	0.243	0.208, 0.283	0.026
> 5.0 days	0.431	0.384, 0.482	Referent
Medical school affiliation			
Major teaching	0.361	0.324, 0.401	0.0155
Graduate teaching	0.164	0.128, 0.209	0.4460
Undergraduate teaching	0.144	0.094, 0.213	0.1648
None	0.211	0.177, 0.252	Referent
Oncology Unit			
Present	0.396	0.353, 0.442	< 0.0001
Absent	0.187	0.164, 0.212	Referent

Disclosures. All authors: No reported disclosures.

575. Evaluation of Risk Factors and Clinical Outcomes of Patients with Vancomycin-Resistant *Enterococcus* Infections

Gauri Chauhan, PharmD¹; Nikunj M. Vyas, PharmD, BCPS²; Todd P. Levin, DO, FACOI, FIDSA³ and Sungwook Kim, PhD³; ¹Jefferson Health New Jersey, Voorhees, New Jersey; ²Jefferson Health – New Jersey, Stratford, New Jersey; ³University of the Sciences, Philadelphia, Pennsylvania

Session: 63. HAI: VRE Epidemiology
Thursday, October 3, 2019: 12:15 PM

Background. Vancomycin-resistant *Enterococci* (VRE) occurs with enhanced frequency in hospitalized patients and are usually associated with poor clinical outcomes. The purpose of this study was to evaluate the risk factors and clinical outcomes of patients with VRE infections.

Methods. This study was an IRB-approved multi-center retrospective chart review conducted at a three-hospital health system between August 2016–November 2018. Inclusion criteria were patients ≥ 18 years and admitted for ≥ 24 hours with cultures positive for VRE. Patients pregnant or colonized with VRE were excluded. The primary endpoint was to analyze the association of potential risk factors with all-cause in-hospital mortality (ACM) and 30-day readmission. The subgroup analysis focused on the association of risk factors with VRE bacteremia. The secondary endpoint was to evaluate the impact of different treatment groups of high dose daptomycin (HDD) (≥ 10 mg/kg/day) vs. low dose daptomycin (LDD) (< 10 mg/kg/day) vs. linezolid (LZD) on ACM and 30-day readmission. Subgroup analysis focused on the difference of length of stay (LOS), length of therapy (LOT), duration of bacteremia (DOB) and clinical success (CS) between the treatment groups.

Results. There were 81 patients included for analysis; overall mortality was observed at 16%. Utilizing multivariate logistic regression analyses, patients presenting from long-term care facilities (LTCF) were found to have increased risk for mortality (OR 4.125, 95% CI 1.149–14.814). No specific risk factors were associated with 30-day readmission. Patients with previous exposure to fluoroquinolones (FQ) and cephalosporins (CPS), nosocomial exposure and history of heart failure (HF) showed association with VRE bacteremia. ACM was similar between HDD vs. LDD vs. LZD (16.7% vs. 15.4% vs. 0%, $P = 0.52$). No differences were seen between LOS, LOT, CS, and DOB between the groups.

Conclusion. Admission from LTCFs was a risk factor associated with in-hospital mortality in VRE patients. Individuals with history of FQ, CPS and nosocomial exposure as well as history of HF showed increased risk of acquiring VRE bacteremia. There was no difference in ACM, LOS, LOT, and DOB between HDD, LDD and LZD.

Disclosures. All authors: No reported disclosures.

576. A Multicenter Epidemiology Study on Risk Factors of Vancomycin-Resistant *Enterococcus* Infections in China: Results from the China Antimicrobial Surveillance Network (CHINET) in 2016

Dongfang Lin, MD¹; Yan Guo, Master¹; Yang Yang, Master of medicine²; Demei Zhu, Bachelor¹ and Fupin Hu, PhD¹; ¹Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, Shanghai, China (People's Republic); ²Institute of Antibiotics, Huashan Hospital, Fudan University, and Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China (People's Republic)

Session: 63. HAI: VRE Epidemiology
Thursday, October 3, 2019: 12:15 PM